GLP-1R Agonists – Label Extensions/Drug Repurposing – Market Overview, Trends, Pricing, Pipeline Analysis, Future Players, Opportunities and Challenges

All the vital news, analysis, and commentary curated by our industry experts.

$9995

Buy Report Download FREE Resources

Published: April 29, 2025 Report Code: GDHCHT584-ST

Report Overview
Key Players
Table of Contents

This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity.

The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.
GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.
Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.

Scope

Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation.

Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing.

Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas.

Overview of current major players in the GLP-1RAs space and potential future players.

GLP-1RAs global market outlook and deals overview.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future.

• Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Novo Nordisk AS
Eli Lilly and Co
Shanghai Minwei Biotechnology Co Ltd
Metsera Inc
Sihuan Pharmaceutical Holdings Group Ltd
Hanmi Pharmaceuticals Co Ltd
Jiangsu Hengrui Medicine Co Ltd
AstraZeneca Plc
PegBio Co Ltd
Beijing QL Biopharmaceutical Co Ltd
Sciwind Biosciences Co Ltd
U.S. National Institutes of Health
Boehringer Ingelheim International GmbH
i2O Therapeutics Inc
Zhejiang Doer Biologics Corp
CSPC Pharmaceutical Group Ltd
Peptron Inc
Carmot Therapeutics Inc
Amogen Pharma Pvt Ltd
BioLingus AG
The United Laboratories International Holdings Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Annovis Bio Inc
ImmunoForge Co Ltd
Biogenomics Ltd
China Pharmaceutical University
Zhejiang Heze Pharmaceutical Technology Co Ltd
Zhuhai United Laboratories Co Ltd
Hangzhou Jiuyuan Gene Engineering Co Ltd
Structure Therapeutics Inc
Altimmune Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Gmax Biopharm LLC
Guangzhou Dazhou Biomedical Technology Co Ltd
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Huadong Medicine Co Ltd
Innovent Biologics Inc
Merck & Co Inc
Neuraly Inc
Onegene Biotechnology Inc
Protheragen Inc
RenaissThera Pvt Ltd
Sekkei Inc
Uni-Bio Science Group Ltd
HEC Pharma Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Cascade Pharmaceuticals Inc
D&D Pharmatech Co Ltd
Huons Global Co Ltd
Immunwork Inc
Leto Laboratories Co Ltd
MetaVia Inc
Pfizer Inc
Qilu Regor Therapeutics Inc
Sanofi
Xintrum Pharmaceuticals Ltd
Gan & Lee Pharmaceuticals Co Ltd
Adocia SAS
AnyGen Co Ltd
Ascendis Pharma AS
AULBIO Co Ltd
BrightGene Bio-Medical Technology Co Ltd
Camurus AB
HK inno.N Corp
Hybio Pharmaceutical Co Ltd
IGC Pharma Inc
Lancaster University
Laxxon Medical GmbH
Poolbeg Pharma Plc
ProGen Co Ltd
Septerna Inc
Shanghai Innogen Pharmaceutical Technology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Sun Pharmaceutical Industries Ltd
Suzhou Wingtech Pharmaceutical Technology Co Ltd
Theertha Biopharma Pvt Ltd
Verdiva Bio Ltd
Vivani Medical Inc
Yunovia Co Ltd
Adare Pharma Solutions
Amgen Inc
Apeloa Pharmaceutical Co Ltd
ApicHope Pharmaceutical Co Ltd
Arecor Therapeutics Plc
Biolexis Therapeutics Inc
Biomea Fusion Inc
Biomed Industries Inc
BioNxt Solutions Inc
California Institute for Biomedical Research
China Medical System Holdings Ltd
Chongqing Chenan BioPharm Co Ltd
CinFina Pharma LLC
Crinetics Pharmaceuticals Inc
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Daewoong Therapeutics Inc
Diabetology (Products) Ltd
Dx&Vx
Efil Bioscience Inc
Entera Bio Ltd
Gilead Sciences Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HangZhou HuiSheng Biotech Pharmaceutical Co Ltd
Hepagene Therapeutics Inc
HighField Biopharmaceuticals, Inc.
Hua Medicine Shanghai Ltd
INVENT Pharmaceuticals Inc
Inventage Lab Inc
iX Biopharma Ltd
Jiangsu Normal University
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
Livzon Pharmaceutical Group Inc
MeiraGTx Holdings Plc
MindRank Ltd
Niedlfree Technologies Pvt Ltd
OPKO Health Inc
Remedium Bio Inc
Scohia Pharma Inc
Shandong New Era Pharmaceutical Co Ltd
SN BioScience Co Ltd
Tharimmune Inc
Viking Therapeutics Inc
vTv Therapeutics Inc
Youngene Therapeutics Co Ltd
Zealand Pharma AS
4Moving Biotech
Abaxys Therapeutics SA
Aerami Therapeutics Holdings Inc
AI Proteins Inc
Akrikhin
Alphamab Oncology
Aprilbio Co Ltd
Ascletis Pharma Inc
Beijing Eastern Biotech Co Ltd
Beijing SL Pharmaceutical Co Ltd
Biora Therapeutics Inc
Bostal Drug Delivery Co Ltd
Bristol-Myers Squibb Co
Chengdu Brilliant Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co Ltd
Closed Loop Medicine Ltd
Coya Therapeutics Inc
Delpor Inc
Duke University
Enteris BioPharma Inc
G2GBIO Inc
GlyTech Inc
Gubra ApS
Halo Therapeutics Ltd
HEC Pharm Group
Hualan Biological Engineering Inc
Iconovo AB
Icure Pharmaceutical Inc
Imagine Pharma LLC
Immupharma Plc
Imperial College London
Innopharmax Inc
Jiangsu Wanbang Biochemical Pharmaceutical Group Co Ltd
Kailera Therapeutics Inc
Kariya Pharmaceuticals IVS
Kunming Yinnuo Medical Technology Co. Ltd.
Lanzhou Institute of Biological Products Co Ltd
Lepu Medical Technology (Beijing) Co Ltd
Mapi Pharma Ltd
MBX Biosciences Inc
Metaphore Biotechnologies Inc
Nanexa AB
National Institute of Biomedical Imaging and Bioengineering
NutriBand Inc
Oramed Pharmaceuticals Inc
Original BioMedicals Co Ltd
Pep2Tango Therapeutics Inc
ProLynx LLC
Qilu Pharmaceutical Co Ltd
QuiaPEG Pharmaceuticals AB
Rani Therapeutics LLC
Rivus Pharmaceuticals Inc
Rose Pharma Inc
R-Pharm
Sail Biomedicines Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sino Biopharmaceutical Ltd
Syracuse University
Terns Pharmaceuticals Inc
Terry Suzhou Pharmaceutical Co Ltd
The University of Adelaide
Twist Bioscience Corp
University of Padova
University of Ulster
Vanderbilt University
Virtici LLC
Wuxi Hebang Biotechnology Co Ltd
Yichang Humanwell Pharmaceutical Co Ltd
Yonsei University College of Medicine
Zhejiang HuaYang Pharmaceutical Co Ltd
Zhongshan Wanhan Pharmaceutical Co Ltd

1 Preface

1.1 Contents

1.2 Abbreviations

1.3 Related Reports

2 Executive Summary

3 GLP-1R Agonists Overview

3.1 What Are GLP-1R Agonists

3.2 GLP-1R in the Body

3.3 History of GLP-1R Agonists

4 Industry Trends

4.1 Oral GLP-1Ras

4.2 Lower Dosing Frequency

4.3 Combination and Dual/Triple Agonists

4.4 Repurposing GLP-1Ras

5 Marketed Products

5.1 Global GLP-1RA Marketed Landscape

5.2 Marketed GLP-1Ras

5.3 Challenges and Opportunities in GLP-1RA Repurposing

5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs

6 Pricing and Reimbursement Assessment Case Study: Ozempic

7 Pipeline Analysis

7.1 Top 20 Indications with GLP-1RAs in Development

7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets

7.3 GLP-1RA Pipeline Candidates

7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?

7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?

7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease

7.7 GLP-1RA Opportunities Beyond Planned Label Expansions

7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome

8 Opportunities and Challenges

8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

8.2 Opportunities: GLP-1RAs in Liver Diseases

8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases

8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases

8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders

8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson’s Disease

8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke

8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases

8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease

8.10 Opportunities: GLP-1RAs in Other Diseases

9 Companies

9.1 Current Major Player: Novo Nordisk

9.2 Current Major Player: Eli Lilly

9.3 Potential Future Players

9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space

10 Market Outlook and Deals

10.1 GLP-1RA Global Market

10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1Ras

11 Appendix

11.1 Bibliography

11.2 Primary Research – KOL Information

11.3 About the Authors

12 Contact Us

GLP-1R Agonists – Label Extensions/Drug Repurposing – Market Overview, Trends, Pricing, Pipeline Analysis, Future Players, Opportunities and Challenges standard reports

Currency USD

Single User

$9,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

GLP-1R Agonists – Label Extensions/Drug Repurposing – Market Overview, Trends, Pricing, Pipeline Analysis, Future Players, Opportunities and Challenges was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Uveitis reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Overweight and Obesity: Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at GLP-1R Agonists – Label Extensions/Drug Repurposing – Market Overview, Trends, Pricing, Pipeline Analysis, Future Players, Opportunities and Challenges in real time.

Access a live GLP-1R Agonists – Label Extensions/Drug Repurposing – Market Overview, Trends, Pricing, Pipeline Analysis, Future Players, Opportunities and Challenges dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

GLP-1R Agonists – Label Extensions/Drug Repurposing – Market Overview, Trends, Pricing, Pipeline Analysis, Future Players, Opportunities and Challenges

Scope

Reasons to Buy

Table of Contents

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports